Profile data is unavailable for this security.
About the company
Sareum Holdings plc is a United Kingdom-based biotechnology company. The principal activity of the Company is the discovery and development of new therapeutic drugs using a combination of skills in biology, computational chemistry and medicinal chemistry. The Company's internal programs focus on distinct dual tyrosine kinase 2 (TYK2)/ Janus kinase 1 (JAK1) inhibitors, which are progressing through preclinical development as therapies for autoimmune diseases and cancers. Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801 is a potential treatment for a range of autoimmune diseases, with an initial focus on psoriasis. It is also developing SDC-1802, a TYK2/JAK1 inhibitor with a potential application for cancer immunotherapy. The Company also has an interest in SRA737, an orally bioavailable small molecule inhibitor of checkpoint kinase 1 (Chk1), a key regulator of important cell cycle checkpoints and a central mediator of the DNA damage response (DDR) network.
- Revenue in GBP (TTM)0.00
- Net income in GBP-4.26m
- Incorporated2004
- Employees5.00
- LocationSareum Holdings PLCUnit 2ALangford Arch, London Road, PampisfordCAMBRIDGE CB22 3FXUnited KingdomGBR
- Phone+44 12 2349 7700Fax+44 12 2349 7701
- Websitehttps://sareum.com/
Peer analysis
Company | Revenue (TTM) | Net income (TTM) |
---|---|---|
ImmuPharma PLC | -69.96k | -2.46m |
Genflow Biosciences PLC | 0.00 | -1.63m |
Synairgen plc | 0.00 | -6.92m |
Cizzle Biotechnology Holdings PLC | 0.00 | -1.72m |
LungLife AI Inc | 21.69k | -3.34m |
Oxford Biodynamics PLC | 617.00k | -11.11m |
OptiBiotix Health PLC | 644.00k | -2.04m |
Hemogenyx Pharmaceuticals PLC | 0.00 | -6.69m |
Skinbiotherapeutics PLC | 161.65k | -2.88m |
Arecor Therapeutics PLC | 4.57m | -8.55m |
Sareum Holdings Plc | 0.00 | -4.26m |
Incanthera PLC | 0.00 | -1.55m |
Shield Therapeutics PLC | 20.88m | -36.17m |
Institutional shareholders
Holder | Shares | % Held |
---|---|---|
Hargreaves Lansdown Asset Management Ltd.as of 01 Jul 2024 | 7.37m | 6.83% |
HSBC Global Asset Management (UK) Ltd.as of 01 Jul 2024 | 4.66m | 4.32% |
IG Markets Ltd.as of 01 Jul 2024 | 649.00k | 0.60% |
Jarvis Investment Management Ltd.as of 01 Jul 2024 | 497.00k | 0.46% |
KW Investment Management Ltd.as of 01 Jul 2024 | 478.00k | 0.44% |
HSBC Bank Plc (Market-Maker)as of 01 Jul 2024 | 287.00k | 0.27% |
Evelyn Partners Investment Management Services Ltd.as of 01 Jul 2024 | 228.00k | 0.21% |
Rowan Dartington & Co. Ltd. (Broker)as of 01 Jul 2024 | 184.00k | 0.17% |
Rathbones Investment Management Ltd.as of 01 Jul 2024 | 179.00k | 0.17% |
Eurizon Capital SGR SpAas of 01 Jul 2024 | 152.00k | 0.14% |